全年营收23.7亿元!中国创新药崛起途中的“诺诚健华样本”

和讯网
Feb 02

近日,诺诚健华交出了一份远超市场预期的年度业绩预告:预计实现收入约23.7亿元,同比激增约134%;预计归母净利润首次扭亏为盈,达到约6.3亿元。这组数据,不仅是诺诚健华对市场承诺的兑现与价值的自证,更堪称中国创新药产业深刻变革途中的一份“标志性文本”。清晰地宣告:那个依赖“烧钱讲故事”获取估值的时代正在落幕,一个考验企业“凭实力盈利”与“全球价值兑现”能力的新纪元,已经来临。跨越拐点,重塑全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10